Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2007. The report serves as a notification regarding transactions of directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a correction to share interest notifications.
Material Changes
The filing details a correction to previously notified increases in interests in Ordinary Share ADRs for specific individuals. This correction follows the re-investment of dividends paid to shareholders on April 12, 2007, at a price of $56.84 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural notification regarding share plan transactions.
Important Facts for Investors
- Transaction Type: Correction to an increase in interests in Ordinary Share ADRs via dividend re-investment.
- Price: $56.84 per ADR.
- Dividend Date: April 12, 2007.
- Affected Individuals and Share Counts:
- Dr. JP Garnier: 717.52 shares
- Mr. D J Phelan: 153.75 shares
- Mr. D M Stout: 74.46 shares
- Regulatory Basis: Notification complies with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).